Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1.

Boelen L, Debebe B, Silveira M, Salam A, Makinde J, Roberts CH, Wang ECY, Frater J, Gilmour J, Twigger K, Ladell K, Miners KL, Jayaraman J, Traherne JA, Price DA, Qi Y, Martin MP, Macallan DC, Thio CL, Astemborski J, Kirk G, Donfield SM, Buchbinder S, Khakoo SI, Goedert JJ, Trowsdale J, Carrington M, Kollnberger S, Asquith B.

Sci Immunol. 2018 Nov 9;3(29). pii: eaao2892. doi: 10.1126/sciimmunol.aao2892.

PMID:
30413420
2.

Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness.

Costa Del Amo P, Lahoz-Beneytez J, Boelen L, Ahmed R, Miners KL, Zhang Y, Roger L, Jones RE, Marraco SAF, Speiser DE, Baird DM, Price DA, Ladell K, Macallan D, Asquith B.

PLoS Biol. 2018 Jun 22;16(6):e2005523. doi: 10.1371/journal.pbio.2005523. eCollection 2018 Jun.

3.

Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa.

Nemat-Gorgani N, Hilton HG, Henn BM, Lin M, Gignoux CR, Myrick JW, Werely CJ, Granka JM, Möller M, Hoal EG, Yawata M, Yawata N, Boelen L, Asquith B, Parham P, Norman PJ.

J Immunol. 2018 Apr 15;200(8):2640-2655. doi: 10.4049/jimmunol.1701780. Epub 2018 Mar 16.

PMID:
29549179
4.

The fate and lifespan of human monocyte subsets in steady state and systemic inflammation.

Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, Bigley V, Flavell RA, Gilroy DW, Asquith B, Macallan D, Yona S.

J Exp Med. 2017 Jul 3;214(7):1913-1923. doi: 10.1084/jem.20170355. Epub 2017 Jun 12.

5.

HIV-1 adaptation to NK cell-mediated immune pressure.

Elemans M, Boelen L, Rasmussen M, Buus S, Asquith B.

PLoS Pathog. 2017 Jun 5;13(6):e1006361. doi: 10.1371/journal.ppat.1006361. eCollection 2017 Jun.

6.

Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans.

Lahoz-Beneytez J, Schaller S, Macallan D, Eissing T, Niederalt C, Asquith B.

Front Immunol. 2017 Apr 25;8:474. doi: 10.3389/fimmu.2017.00474. eCollection 2017.

7.

Human T Cell Memory: A Dynamic View.

Macallan DC, Borghans JA, Asquith B.

Vaccines (Basel). 2017 Feb 4;5(1). pii: E5. doi: 10.3390/vaccines5010005. Review.

8.

How lymphocytes add up.

Asquith B, de Boer RJ.

Nat Immunol. 2016 Dec 16;18(1):12-13. doi: 10.1038/ni.3636. No abstract available.

9.

Human Stem Cell-like Memory T Cells Are Maintained in a State of Dynamic Flux.

Ahmed R, Roger L, Costa Del Amo P, Miners KL, Jones RE, Boelen L, Fali T, Elemans M, Zhang Y, Appay V, Baird DM, Asquith B, Price DA, Macallan DC, Ladell K.

Cell Rep. 2016 Dec 13;17(11):2811-2818. doi: 10.1016/j.celrep.2016.11.037.

10.

Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives.

Lahoz-Beneytez J, Elemans M, Zhang Y, Ahmed R, Salam A, Block M, Niederalt C, Asquith B, Macallan D.

Blood. 2016 Jun 30;127(26):3431-8. doi: 10.1182/blood-2016-03-700336. Epub 2016 May 2.

11.

BIITE: A Tool to Determine HLA Class II Epitopes from T Cell ELISpot Data.

Boelen L, O'Neill PK, Quigley KJ, Reynolds CJ, Maillere B, Robinson JH, Lertmemongkolchai G, Altmann DM, Boyton RJ, Asquith B.

PLoS Comput Biol. 2016 Mar 8;12(3):e1004796. doi: 10.1371/journal.pcbi.1004796. eCollection 2016 Mar.

12.

Reconciling Estimates of Cell Proliferation from Stable Isotope Labeling Experiments.

Ahmed R, Westera L, Drylewicz J, Elemans M, Zhang Y, Kelly E, Reljic R, Tesselaar K, de Boer RJ, Macallan DC, Borghans JA, Asquith B.

PLoS Comput Biol. 2015 Oct 5;11(10):e1004355. doi: 10.1371/journal.pcbi.1004355. eCollection 2015 Oct.

13.

Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach.

Laydon DJ, Bangham CR, Asquith B.

Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675). pii: 20140291. doi: 10.1098/rstb.2014.0291. Review.

14.

HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.

Niederer HA, Laydon DJ, Melamed A, Elemans M, Asquith B, Matsuoka M, Bangham CR.

Virol J. 2014 Sep 30;11:172. doi: 10.1186/1743-422X-11-172.

15.

Quantification of HTLV-1 clonality and TCR diversity.

Laydon DJ, Melamed A, Sim A, Gillet NA, Sim K, Darko S, Kroll JS, Douek DC, Price DA, Bangham CR, Asquith B.

PLoS Comput Biol. 2014 Jun 19;10(6):e1003646. doi: 10.1371/journal.pcbi.1003646. eCollection 2014 Jun.

16.

Rates of CTL killing in persistent viral infection in vivo.

Elemans M, Florins A, Willems L, Asquith B.

PLoS Comput Biol. 2014 Apr 3;10(4):e1003534. doi: 10.1371/journal.pcbi.1003534. eCollection 2014 Apr.

17.

Can non-lytic CD8+ T cells drive HIV-1 escape?

Seich Al Basatena NK, Chatzimichalis K, Graw F, Frost SD, Regoes RR, Asquith B.

PLoS Pathog. 2013;9(11):e1003656. doi: 10.1371/journal.ppat.1003656. Epub 2013 Nov 14.

18.

Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans.

Westera L, Drylewicz J, den Braber I, Mugwagwa T, van der Maas I, Kwast L, Volman T, van de Weg-Schrijver EH, Bartha I, Spierenburg G, Gaiser K, Ackermans MT, Asquith B, de Boer RJ, Tesselaar K, Borghans JA.

Blood. 2013 Sep 26;122(13):2205-12. doi: 10.1182/blood-2013-03-488411. Epub 2013 Aug 14.

19.

Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.

Gillet NA, Cook L, Laydon DJ, Hlela C, Verdonck K, Alvarez C, Gotuzzo E, Clark D, Farré L, Bittencourt A, Asquith B, Taylor GP, Bangham CR.

PLoS Pathog. 2013;9(4):e1003263. doi: 10.1371/journal.ppat.1003263. Epub 2013 Apr 4.

20.

HTLV-1: persistence and pathogenesis.

Cook LB, Elemans M, Rowan AG, Asquith B.

Virology. 2013 Jan 5;435(1):131-40. doi: 10.1016/j.virol.2012.09.028. Review. No abstract available.

21.

In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection.

O'Connor GM, Seich Al Basatena NK, Olavarria V, MacNamara A, Vine A, Ying Q, Hisada M, Galvão-Castro B, Asquith B, McVicar DW.

Hum Immunol. 2012 Aug;73(8):783-7. doi: 10.1016/j.humimm.2012.05.006. Epub 2012 May 17.

22.

The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter?

Elemans M, Seich Al Basatena NK, Asquith B.

PLoS Comput Biol. 2012;8(2):e1002381. doi: 10.1371/journal.pcbi.1002381. Epub 2012 Feb 23.

23.

Viral expression directs the fate of B cells in bovine leukemia virus-infected sheep.

Florins A, de Brogniez A, Elemans M, Bouzar AB, François C, Reichert M, Asquith B, Willems L.

J Virol. 2012 Jan;86(1):621-4. doi: 10.1128/JVI.05718-11. Epub 2011 Oct 26.

24.

KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection.

Seich Al Basatena NK, Macnamara A, Vine AM, Thio CL, Astemborski J, Usuku K, Osame M, Kirk GD, Donfield SM, Goedert JJ, Bangham CR, Carrington M, Khakoo SI, Asquith B.

PLoS Pathog. 2011 Oct;7(10):e1002270. doi: 10.1371/journal.ppat.1002270. Epub 2011 Oct 13.

25.

Safety of long-term treatment of HAM/TSP patients with valproic acid.

Olindo S, Belrose G, Gillet N, Rodriguez S, Boxus M, Verlaeten O, Asquith B, Bangham C, Signaté A, Smadja D, Lezin A, Césaire R, Willems L.

Blood. 2011 Dec 8;118(24):6306-9. doi: 10.1182/blood-2011-04-349910. Epub 2011 Oct 13.

26.

Why don't CD8+ T cells reduce the lifespan of SIV-infected cells in vivo?

Elemans M, Seich Al Basatena NK, Klatt NR, Gkekas C, Silvestri G, Asquith B.

PLoS Comput Biol. 2011 Sep;7(9):e1002200. doi: 10.1371/journal.pcbi.1002200. Epub 2011 Sep 29.

27.

Short communication an interferon-γ ELISPOT assay with two cytotoxic T cell epitopes derived from HTLV-1 tax region 161-233 discriminates HTLV-1-associated myelopathy/tropical spastic paraparesis patients from asymptomatic HTLV-1 carriers in a Peruvian population.

Best I, López G, Talledo M, MacNamara A, Verdonck K, González E, Tipismana M, Asquith B, Gotuzzo E, Vanham G, Clark D.

AIDS Res Hum Retroviruses. 2011 Nov;27(11):1207-12. doi: 10.1089/AID.2011.0029. Epub 2011 May 9.

PMID:
21453202
28.

Quantification of the relative importance of CTL, B cell, NK cell, and target cell limitation in the control of primary SIV-infection.

Elemans M, Thiébaut R, Kaur A, Asquith B.

PLoS Comput Biol. 2011 Mar;7(3):e1001103. doi: 10.1371/journal.pcbi.1001103. Epub 2011 Mar 3.

29.

In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.

Hilburn S, Rowan A, Demontis MA, MacNamara A, Asquith B, Bangham CR, Taylor GP.

J Infect Dis. 2011 Feb 15;203(4):529-36. doi: 10.1093/infdis/jiq078. Epub 2011 Jan 5.

30.

Quantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes.

Kadolsky UD, Asquith B.

PLoS Comput Biol. 2010 Nov 4;6(11):e1000981. doi: 10.1371/journal.pcbi.1000981.

31.

HLA class I binding of HBZ determines outcome in HTLV-1 infection.

Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CR, Asquith B.

PLoS Pathog. 2010 Sep 23;6(9):e1001117. doi: 10.1371/journal.ppat.1001117.

32.

Earlier onset of delta-retrovirus-induced leukemia after splenectomy.

Florins A, Reichert M, Asquith B, Bouzar AB, Jean G, François C, Jasik A, Burny A, Kettmann R, Willems L.

PLoS One. 2009 Sep 14;4(9):e6943. doi: 10.1371/journal.pone.0006943.

33.

Measurement of proliferation and disappearance of rapid turnover cell populations in human studies using deuterium-labeled glucose.

Macallan DC, Asquith B, Zhang Y, de Lara C, Ghattas H, Defoiche J, Beverley PC.

Nat Protoc. 2009;4(9):1313-27. doi: 10.1038/nprot.2009.117. Epub 2009 Aug 20.

PMID:
19696750
34.

Gene activation therapy: from the BLV model to HAM/TSP patients.

Lezin A, Olindo S, Belrose G, Signate A, Cesaire R, Smadja D, Macallan D, Asquith B, Bangham C, Bouzar A, Gillet N, Defoiche J, Florins A, Verlaeten O, Burny A, Willems L.

Front Biosci (Schol Ed). 2009 Jun 1;1:205-15. Review.

PMID:
19482696
35.

The avidity and lytic efficiency of the CTL response to HTLV-1.

Kattan T, MacNamara A, Rowan AG, Nose H, Mosley AJ, Tanaka Y, Taylor GP, Asquith B, Bangham CR.

J Immunol. 2009 May 1;182(9):5723-9. doi: 10.4049/jimmunol.0900069.

36.

T-cell epitope prediction: rescaling can mask biological variation between MHC molecules.

MacNamara A, Kadolsky U, Bangham CR, Asquith B.

PLoS Comput Biol. 2009 Mar;5(3):e1000327. doi: 10.1371/journal.pcbi.1000327. Epub 2009 Mar 20.

37.

Lymphocyte kinetics in health and disease.

Asquith B, Borghans JA, Ganusov VV, Macallan DC.

Trends Immunol. 2009 Apr;30(4):182-9. doi: 10.1016/j.it.2009.01.003. Epub 2009 Mar 13. Review. Erratum in: Trends Immunol. 2009 Oct;30(10):467.

PMID:
19286425
38.

The immune control of HTLV-1 infection: selection forces and dynamics.

Bangham CR, Meekings K, Toulza F, Nejmeddine M, Majorovits E, Asquith B, Taylor GP.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2889-903. Review.

PMID:
19273242
39.
40.

Reduction of B cell turnover in chronic lymphocytic leukaemia.

Defoiche J, Debacq C, Asquith B, Zhang Y, Burny A, Bron D, Lagneaux L, Macallan D, Willems L.

Br J Haematol. 2008 Oct;143(2):240-7. doi: 10.1111/j.1365-2141.2008.07348.x. Epub 2008 Aug 15.

PMID:
18710389
41.

How does HTLV-I persist despite a strong cell-mediated immune response?

Asquith B, Bangham CR.

Trends Immunol. 2008 Jan;29(1):4-11. Epub 2007 Nov 26.

42.

Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients.

Lezin A, Gillet N, Olindo S, Signaté A, Grandvaux N, Verlaeten O, Belrose G, de Carvalho Bittencourt M, Hiscott J, Asquith B, Burny A, Smadja D, Césaire R, Willems L.

Blood. 2007 Nov 15;110(10):3722-8. Epub 2007 Aug 23.

43.

In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection.

Asquith B, Zhang Y, Mosley AJ, de Lara CM, Wallace DL, Worth A, Kaftantzi L, Meekings K, Griffin GE, Tanaka Y, Tough DF, Beverley PC, Taylor GP, Macallan DC, Bangham CR.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8035-40. Epub 2007 May 1.

44.

In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques.

Asquith B, McLean AR.

Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6365-70. Epub 2007 Apr 2.

45.

Quantifying HTLV-I dynamics.

Asquith B, Bangham CR.

Immunol Cell Biol. 2007 Jun;85(4):280-6. Epub 2007 Mar 20. Review.

PMID:
17372609
46.

In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection.

Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, Griffin GE, Taylor GP, Tough DF, Beverley PC, Macallan DC.

Immunology. 2007 Jun;121(2):258-65. Epub 2007 Mar 7.

47.

Cell dynamics and immune response to BLV infection: a unifying model.

Florins A, Gillet N, Asquith B, Boxus M, Burteau C, Twizere JC, Urbain P, Vandermeers F, Debacq C, Sanchez-Alcaraz MT, Schwartz-Cornil I, Kerkhofs P, Jean G, Théwis A, Hay J, Mortreux F, Wattel E, Reichert M, Burny A, Kettmann R, Bangham C, Willems L.

Front Biosci. 2007 Jan 1;12:1520-31. Review.

48.

Spleen-dependent turnover of CD11b peripheral blood B lymphocytes in bovine leukemia virus-infected sheep.

Florins A, Gillet N, Asquith B, Debacq C, Jean G, Schwartz-Cornil I, Bonneau M, Burny A, Reichert M, Kettmann R, Willems L.

J Virol. 2006 Dec;80(24):11998-2008. Epub 2006 Oct 11.

49.

Peripheral blood B-cell death compensates for excessive proliferation in lymphoid tissues and maintains homeostasis in bovine leukemia virus-infected sheep.

Debacq C, Gillet N, Asquith B, Sanchez-Alcaraz MT, Florins A, Boxus M, Schwartz-Cornil I, Bonneau M, Jean G, Kerkhofs P, Hay J, Théwis A, Kettmann R, Willems L.

J Virol. 2006 Oct;80(19):9710-9.

50.

Quantifying lymphocyte kinetics in vivo using carboxyfluorescein diacetate succinimidyl ester (CFSE).

Asquith B, Debacq C, Florins A, Gillet N, Sanchez-Alcaraz T, Mosley A, Willems L.

Proc Biol Sci. 2006 May 7;273(1590):1165-71.

Supplemental Content

Loading ...
Support Center